berberine has been researched along with Cardiac Remodeling, Ventricular in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study aimed to test the hypothesis that berberine, a plant-derived anti-oxidant, attenuates adverse left ventricular remodelling and improves cardiac function in a rat model of myocardial infarction (MI)." | 7.80 | Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy. ( Bourantas, CV; Chen, SL; Iqbal, J; Li, JJ; Li, MH; Mi, QY; Tian, NL; Yang, SH; Yu, YH; Zhang, YJ; Zhao, SL, 2014) |
| "Emerging evidence indicates that leptin may be a potential new target in chronic heart failure (CHF) treatment." | 7.74 | Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. ( Dai, DZ; Dai, Y; Na, T; Tang, XY, 2007) |
| "Cardiac fibrosis is a crucial aspect of cardiac remodeling that can severely affect cardiac function." | 5.51 | Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. ( Che, Y; Jin, YG; Shen, DF; Wang, SS; Wang, ZP; Wu, QQ; Yuan, Y, 2019) |
| "Berberine is a isoquinoline quarternary alkaloid from plants that has been associated with anti-inflammatory, anti-oxidative, and cardioprotective properties." | 5.46 | Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. ( Allijn, IE; Chong, SY; Czarny, BMS; da Silva, AE; de Kleijn, DPV; Lam, CSP; Metselaar, JM; Pastorin, G; Schiffelers, RM; Storm, G; Wang, JW; Wang, X; Weiler, M, 2017) |
| "Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure." | 5.40 | Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014) |
| "Compared with the sham group, rats of the TAC group showed significantly increased cardiac hypertrophy and fibrosis, which could be ameliorated by treatment with berberine." | 3.96 | Berberine Attenuates Cardiac Hypertrophy Through Inhibition of mTOR Signaling Pathway. ( Chen, J; Chen, X; Cheng, C; Huang, S; Jiang, X; Liu, S; Xu, M, 2020) |
| "The present study aimed to test the hypothesis that berberine, a plant-derived anti-oxidant, attenuates adverse left ventricular remodelling and improves cardiac function in a rat model of myocardial infarction (MI)." | 3.80 | Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy. ( Bourantas, CV; Chen, SL; Iqbal, J; Li, JJ; Li, MH; Mi, QY; Tian, NL; Yang, SH; Yu, YH; Zhang, YJ; Zhao, SL, 2014) |
| "Remodeling of the pulmonary artery is a major feature of pulmonary artery hypertension, and CPU86017, a derivative of berberine, is known to effectively alleviate hypoxic pulmonary hypertension (HPH)." | 3.74 | CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation. ( Dai, DZ; Dai, Y; Li, N, 2008) |
| "Emerging evidence indicates that leptin may be a potential new target in chronic heart failure (CHF) treatment." | 3.74 | Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. ( Dai, DZ; Dai, Y; Na, T; Tang, XY, 2007) |
| "Cardiac fibrosis is a crucial aspect of cardiac remodeling that can severely affect cardiac function." | 1.51 | Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats. ( Che, Y; Jin, YG; Shen, DF; Wang, SS; Wang, ZP; Wu, QQ; Yuan, Y, 2019) |
| "Berberine is a isoquinoline quarternary alkaloid from plants that has been associated with anti-inflammatory, anti-oxidative, and cardioprotective properties." | 1.46 | Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. ( Allijn, IE; Chong, SY; Czarny, BMS; da Silva, AE; de Kleijn, DPV; Lam, CSP; Metselaar, JM; Pastorin, G; Schiffelers, RM; Storm, G; Wang, JW; Wang, X; Weiler, M, 2017) |
| "Cardiac hypertrophy is a maladaptive change in response to pressure overload, and is also an important risk for developing heart failure." | 1.40 | Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. ( Chen, SL; Iqbal, J; Li, B; Li, MH; Mao, WX; Mi, QY; Wang, ZM; Xie, HG; Yang, SH; Yu, YH; Zhang, YJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Che, Y | 1 |
| Shen, DF | 1 |
| Wang, ZP | 1 |
| Jin, YG | 1 |
| Wu, QQ | 1 |
| Wang, SS | 1 |
| Yuan, Y | 1 |
| Chen, X | 1 |
| Jiang, X | 1 |
| Cheng, C | 1 |
| Chen, J | 1 |
| Huang, S | 1 |
| Xu, M | 1 |
| Liu, S | 1 |
| Ding, L | 1 |
| Li, S | 2 |
| Wang, F | 1 |
| Xu, J | 1 |
| Wang, B | 1 |
| Kou, J | 1 |
| Wang, Y | 1 |
| Cao, W | 1 |
| Li, G | 1 |
| Xing, W | 1 |
| Zhang, M | 1 |
| Geng, F | 1 |
| Yang, H | 1 |
| Zhang, H | 1 |
| Zhang, X | 1 |
| Li, J | 1 |
| Dong, L | 1 |
| Gao, F | 1 |
| Li, MH | 2 |
| Zhang, YJ | 2 |
| Yu, YH | 2 |
| Yang, SH | 2 |
| Iqbal, J | 2 |
| Mi, QY | 2 |
| Li, B | 1 |
| Wang, ZM | 1 |
| Mao, WX | 1 |
| Xie, HG | 1 |
| Chen, SL | 2 |
| Bourantas, CV | 1 |
| Li, JJ | 1 |
| Zhao, SL | 1 |
| Tian, NL | 1 |
| Allijn, IE | 1 |
| Czarny, BMS | 1 |
| Wang, X | 1 |
| Chong, SY | 1 |
| Weiler, M | 1 |
| da Silva, AE | 1 |
| Metselaar, JM | 1 |
| Lam, CSP | 1 |
| Pastorin, G | 1 |
| de Kleijn, DPV | 1 |
| Storm, G | 1 |
| Wang, JW | 1 |
| Schiffelers, RM | 1 |
| Li, N | 1 |
| Dai, DZ | 2 |
| Dai, Y | 2 |
| Carlomagno, G | 1 |
| Pirozzi, C | 1 |
| Mercurio, V | 1 |
| Ruvolo, A | 1 |
| Fazio, S | 1 |
| Na, T | 1 |
| Tang, XY | 1 |
| Zhao, HP | 1 |
| Hong, Y | 1 |
| Xie, JD | 1 |
| Xie, XR | 1 |
| Wang, J | 1 |
| Fan, JB | 1 |
1 trial available for berberine and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome.
Topics: Anticholesteremic Agents; Berberine; Cardiotonic Agents; Dietary Supplements; Fatty Alcohols; Female | 2012 |
10 other studies available for berberine and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Protective role of berberine in isoprenaline-induced cardiac fibrosis in rats.
Topics: Animals; Berberine; Cardiomyopathies; Cell Transdifferentiation; Cells, Cultured; Coculture Techniqu | 2019 |
Berberine Attenuates Cardiac Hypertrophy Through Inhibition of mTOR Signaling Pathway.
Topics: Animals; Atrial Natriuretic Factor; Berberine; Cell Line; Disease Models, Animal; Fibrosis; Hypertro | 2020 |
Berberine improves dietary-induced cardiac remodeling by upregulating Kruppel-like factor 4-dependent mitochondrial function.
Topics: Animals; Berberine; Dietary Supplements; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; | 2021 |
Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats.
Topics: Actins; Animals; Berberine; Blood Glucose; Cell Differentiation; Cell Proliferation; Cells, Cultured | 2018 |
Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy.
Topics: Animals; Arterial Pressure; Autophagy; Berberine; Blotting, Western; Body Weight; Cardiomegaly; Card | 2014 |
Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy.
Topics: Animals; Autophagy; Berberine; Echocardiography; Myocardial Infarction; Myocytes, Cardiac; p38 Mitog | 2014 |
Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cardiotonic Agents; Heart; Interleukin-6; Liposomes; M | 2017 |
CPU86017 and its isomers improve hypoxic pulmonary hypertension by attenuating increased ETA receptor expression and extracellular matrix accumulation.
Topics: Animals; Berberine; Extracellular Matrix; Gene Expression Regulation; Hypertension, Pulmonary; Hypox | 2008 |
Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017.
Topics: Alkyl and Aryl Transferases; Animals; Anti-Arrhythmia Agents; Antioxidants; Aspartic Acid Endopeptid | 2007 |
[Effect of berberine on left ventricular remodeling in renovascular hypertensive rats].
Topics: Animals; Berberine; Collagen; Cyclic AMP; Cyclic GMP; Hypertension, Renovascular; Male; Myocardium; | 2007 |